Press Releases – Page 2 – CellCentric

Press and media

Press releases

More regular updates and key information, updates and news can be found on the CellCentric LinkedIn page.

CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm

12 September 2023 Press Release

CellCentric announces $25m strategic investment from Pfizer

11 July 2023 Press Release

CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma

29 June 2023 Press Release

CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma

13 June 2023 Press Release

CellCentric presents early haem clinical data at ASH

11 December 2022 Press Release

CellCentric to present haem clinical data at ASH

4 November 2022 Press Release

CellCentric strengthens leadership team

6 April 2022 Press Release

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

26 January 2022 Press Release

IND Open: CellCentric expanding clinical trials into the US

27 April 2021 Press Release

CellCentric’s first-in-class p300/CBP inhibitor CCS1477 publishes in Cancer Discovery

11 January 2021 Press Release

CellCentric raises $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477

22 October 2020 Press Release

CellCentric signs agreement with the PCCTC for Phase II clinical trial expansion into the US

7 April 2020 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug